Drugs / NEX-18a
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05048498 | Apr 2021 → Feb 2022 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Nanexa AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEX-18a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05048498 ↗ |
| Route | Subcutaneous | “NEX-18a will be given as a single subcutaneous injection.” NCT05048498 ↗ |